Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 3NET 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1Neoplasm Metastasis 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gallium-68 × Genitourinary × Clear all
NCT02391025 2023-06-18

Gallium-68 Citrate PET Used in Prostate Cancer

University of California, San Francisco

Phase EARLY_PHASE1 Completed
39 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡